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Patients in whom acid-fast bacilli smear-positive pulmonary tuber-
culosis was newly diagnosed were randomized to receive 400 mg
moxifloxacin, 300 mg isonaizid, or 600 mg rifampin daily for 5 days.
Sixteen-hour overnight sputa collections were made for the 2 days
before and for 5 days of monotherapy. Bactericidal activity was
estimated by the time taken to kill 50% of viable bacilli (vt50)a n d
the fall in sputum viable count during the first 2 days designated
astheearlybactericidalactivity(EBA).Themeanvt50ofmoxifloxacin
was 0.88 days (95% confidence interval [CI], 0.43–1.33 days) and
the meanEBA was 0.53 (95% CI 0.28–0.79). For the isoniazid group,
the mean vt50 was 0.46 days (95% CI, 0.31–0.61 days) and the mean
EBA was 0.77 (95% CI, 0.54–1.00). For rifampin, the mean vt50 was
0.71 days (95% CI, 0.48–0.95 days) and the mean EBA was 0.28
(95% CI, 0.15–0.41). Using the EBA method, isoniazid was signifi-
cantly more active than rifampin (p  0.01) but not moxifloxacin.
Usingthevt50method,isoniazidwasmoreactivethanbothrifampin
and moxifloxacin (p  0.03). Moxifloxacin has an activity similar
to rifampin in human subjects with pulmonary tuberculosis, sug-
gesting that it should undergo further assessment as part of a short
course regimen for the treatment of drug-susceptible tuberculosis.
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The continuing increase in tuberculosis infection and mortality
has prompted researchers to seek new drugs to improve treat-
ment (1). Since the introduction of rifampin and the rediscovery
of the place of pyrazinamide in therapy, there has been no
improvementintuberculosistherapeuticregimens(2,3).Inaddi-
tion, the prevalence of multiple drug resistance is rising world-
wide, providing another stimulus to drug development (1, 4).
The ﬂuorquinolones have been studied for their therapeutic
potential in the management of tuberculosis (5). These bacteri-
cidal drugs, which inhibit DNA gyrase, are highly active against
Mycobacterium tuberculosis, including strains resistant to ﬁrst-
line drugs (6, 7). The excellent in vitro activity is conﬁrmed by
bactericidal activity in a mouse model (8). Moxiﬂoxacin has been
shown to inhibit the growth of the main species of mycobacteria
infecting humans (7, 9). Studies of the activity of moxiﬂoxacin
in mouse models also suggest that it has important bactericidal
activity (10, 11).
Early phase studies of ciproﬂoxacin and a controlled clinical
trial demonstrate useful bactericidal activity in humans (12–14).
Patients with tuberculosis who were treated with rifampin, isoni-
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azid, and ciproﬂoxacin remained culture-positive for a more
prolonged period than patients treated with a standard four-
drug regimen, and there was a trend toward a higher relapse
rate among patients receiving ciproﬂoxacin, suggesting that this
regimen had inferior sterilizing ability (12). A recent study dem-
onstrated that high cure rates could be obtained with regimens
of 4 to 5 months, which contained oﬂoxacin for the ﬁrst 3 months
(15). Quinolones are now used in patients who are not able
to tolerate ﬁrst-line agents or who are infected with multiple
drug–resistant strains (16).
Bactericidal activity of antituberculosis antibiotics is important
early in the course of treatment by ensuring a rapid reduction in
the infective load and later in killing semidormant organisms to
sterilize the lesions (17, 18). The ﬁrst of these characteristics is
testedinmonotherapystudiesalsocalledearlybactericidalactivity
(EBA) studies. These Phase II trials form an important part of
the development of new antituberculosis drug (19, 20), giving
conﬁrmation that the activity demonstrated in vitro and in animal
studies is translated into human subjects. It is also possible to
compare the relative activity of the drugs with control regimens
examined at the same time and with historic controls. In this
paper, the results of a trial comparing moxiﬂoxacin with rifampin
and isoniazid are reported.
METHODS
Study Location
Patients were recruited from those presenting to the Kibong’oto Na-
tional Tuberculosis Hospital, Sanya Juu, Tanzania with acid-fast bacilli
smear–positive pulmonary tuberculosis.
Ethical Considerations
The study was approved by the ethical committee of the Kilimanjaro
Christian Medical College, the National Institute of Medical Research,
and the National Aids Control Program of Tanzania. Each patient gave
witnessed oral consent.
Patients
Inclusion criteria for the study were (1) presence of acid alcohol–fast
organisms found in a Ziehl-Neelsen–stained smear of sputum, (2) mild
to moderate disease on clinical grounds, (3) age over 18, (4) no prior
chemotherapy, (5) production of an adequate volume of sputum, (6)
weight between 40 and 60 kg, (7) consent to human immunodeﬁciency
virus (HIV) serology. Patients were excluded from the study if they had
severe or rapidly progressive disease or had any serious concomitant
condition or renal or hepatic failure as judged by the admitting physician.
Patients were also excluded if there was a history of hypersensitivity to
any of the trial agents.
HIV Serology
After counseling and informed consent, patients serum was collected
for an HIV test. The presence of HIV 1 and 2 antibodies were detected
usingtwoEnzymeimmunoassays:Murex1.2.0(MurexBiotechLimited,
Dartford, UK) and Vironostika, HIV Uni-Form IIplus O (Organon Tek-Gosling, Uiso, Sam, et al.: Bactericidal Activity of Moxifloxacin 1343
nika bv, Boxtel, Netherlands). Patients were considered to be HIV-
positive only if both tests gave a positive result.
Regimens Employed
Patients were randomized by lot to receive one of the following regi-
mens: isoniazid, 300 mg daily; rifampin, 600 mg daily; or moxiﬂoxacin,
400 mg daily for 5 days. Patients had two sputum collections before
therapy was started. After completion of 5 days of monotherapy, pa-
tients were commenced on standard chemotherapy consisting of rifam-
pin, isoniazid, pyrazinamide, and ethambutol in the intensive phase.
Measuring Sputum Viable Count
Sputum collection commenced from 4:00 p.m. on Day 0 (the day of
admission) to 8:00 a.m. the next morning and continued daily during
thedurationoftreatment,i.e.,twopretreatmentcollectionsandacollec-
tion for each day of treatment. Sputum was collected in 200 ml, wide-
mouthed, screw-capped, plastic “honey pots.” The specimens were
transported on ice each morning to the Kilimanjaro Christian Medical
College for processing.
Bacteriologic Procedures
Sputum viable count was measured as follows. The specimen was ho-
mogenizedby addingaTeﬂon-coated followerbarand stirringmagneti-
cally for 30 minutes. Five milliliters of the homogenized sputum was
transferred to a 20-ml sterile universal plastic bottle, and an equal
volume of 1:10 dithiothreitol (Sputasol; Oxoid, Basingstoke, UK) was
added to produce a ﬁnal ratio of 1 (dithiothreitol) to 1 (sputum). The
sample was vortex-mixed for 20 seconds and then shaken mechanically
for 15to 20 minutes. Thedigested sputum samples wereused to prepare
a dilution series of: neat, 1  101,1 102,1 103,1 104, and
1  105 made up in 0.2% bovine albumin. An aliquot of 100 l of the
neat sputum:sputasol admix was inoculated in duplicate onto 7H11
MiddlebrookagarmadeselectivebytheadditionofPolymyxinBsulfate
200 units/ml, Carbenicillin (100 mg/L), Trimethoprim lactate (20 mg/L),
Amphotericin B (100 mg/L), using Selectatabs (Mast, Bootle, UK). A
series of 50 l aliquots of the dilutions were made on between 4 and
6duplicate platesontoselective 7H11Middlebrookmedium. Theplates
were incubated in a humidiﬁed atmosphere for 3 weeks. The number
of colonies was read on each plate, and the sputum viable count was
calculated using the dilution that provided a count of less than 80
colonies. Drug susceptibility testing was not performed on the isolates
obtained in this study.
Calculation of Bactericidal Activity
Time to reduce viable bacilli count by 50%. The results of sputum viable
count (the pretreatment sputa colony count was calculated as the mean
of the two pretreatment samples) were ﬁtted to a single phase expo-
nential decay curve as described previously using the equation V 
Mekt  S, where V is the viable count, M is the number of bacteria
susceptible to antibiotic action, e is the Napierian constant, k is the
exponential decay constant, t is the time, and S is the plateau reached
at the end of the study (17). Curve ﬁtting was performed using the
GraphPad Prism program (GraphPad Software, San Diego, CA). Re-
sultswere onlyacceptedif thegoodnessof ﬁt,measuredby acalculation
of r 2, was greater than 0.95. Using values of k derived from the curve
ﬁtting, it was possible to calculate the time (in days) taken to reduce
the viable count by 50% (vt50) using the formula vt50  ln(0.5)/k (17).
When curves failed to ﬁt the model, discrepant values were removed
using the rule base described previously (17). Brieﬂy, the single point
TABLE 1. DEMOGRAPHIC DATA OF PATIENTS IN TRIAL
Isoniazid Group Moxifloxacin Group Rifampin Group
Variable (n  16)( n  13)( n  14) Test p Value
Male (%) 13 (81) 11 (85) 13 (93) 2 test 0.65
HIV-positive (%) 1 (6) 3 (23) 1 (7) 2 test 0.31
Median age, yr (range) 33 (20–54) 32 (21–60) 28.5 (18–70) Kruskal–Wallis test 0.4
Mean weight, kg (SD) 48.6 (4.7) 52.8 (4.4) 53.9 (5.2) t test 0.01
Definition of abbreviation: HIV  human immunodeficiency virus.
was removed sequentially and taking the remaining points a new value
for r 2 was recalculated. All possible combinations of data were then
calculated, and the best ﬁt was compared. If only one change brought
the r 2 to above 0.95, that result was accepted, but if more than one of
the deletions brought a value of r 2 above 0.95, the data set with the
lowest variance was accepted as the best estimate and was included in
further calculations. If removal of a single point was insufﬁcient, then an
additional point was removed provided that at least four points were
available. The results of the recalculation were treated as mentioned
previously.
EBAcalculation. MeasurementofEBAdependsoncalculatinghalf
of the ratio between the Day 0 (the mean of both pretreatment sputa
collections) and Day 2 viable counts expressed as a log using the equa-
tion: EBA  (log10 cfu/ml S0  log10 cfu/ml S2)/2, where S0 and S2 are
the initial (mean of the two pretreatment samples) and Day 2 colony
counts, respectively (18).
Statistical Tests
Data were entered into an Excel spreadsheet. Curve ﬁtting was done
using GraphPad Prism. All other statistical tests were performed using
SPSS 9.0.
RESULTS
A total of 43 patients with smear-positive pulmonary tuberculo-
sis, of whom 37 (86%) were male, were enrolled into the study
and randomized to receive therapy as follows: isoniazid, 16 (one
HIV-positive); moxiﬂoxacin, 13 (threeHIV-positive); and rifam-
pin, 14 (one HIV-positive). The only signiﬁcant difference in
demographics between the groups was that the mean weight of
patients in the isoniazid arm was signiﬁcantly lower than both
moxiﬂoxacin and rifampin arms. These data are described in full
in Table 1.
Calculation of Bactericidal Activity
Time to reduce viable count 50%. In the moxiﬂoxacin group, the
data of 8 out of 13 subjects ﬁtted the model without adjustment
and that of 3 subjects ﬁtted it further with reiteration. A total
of two subjects were excluded because they had less than four
data points making it impossible to estimate vt50 reliably. An
example of the decline in sputum viable count for a patient
treated with moxiﬂoxacin is illustrated in Figure 1A. Out of 16
subjects in the isoniazid group, the data of 11 subjects ﬁtted the
exponential decay model without adjustment and that of 2 ﬁtted
the model with reiteration. Three patients were excluded be-
cause they had less than four data points. An example of the
decline in sputum viable count in a patient treated with isoniazid
is illustrated in Figure 1B. Within the rifampin group, the data
of 4 out of 14 subjects ﬁtted the model without adjustment and
that of 4 subjects ﬁtted it with reiteration. A total of 6 subjects
were excluded because they had less than four data points. An
example of the decline in sputum viable count for patients
treatedwithrifampin isillustratedinFigure1C. Themeanvalues
for vt50 are recorded in Table 2. Using the Kruskal–Wallis analy-
sis of variance, we showed that isoniazid group had a higher
bactericidal activity than both rifampin and moxiﬂoxacin groups
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Figure 1. (A) Graph illustrating the fall in sputum viable count (cfu/ml)
for a patient treated with isoniazid. (B) Graph illustrating the fall in
sputum viable count (cfu/ml) for a patient treated with moxifloxacin.
(C) Graph illustrating the fall in sputum viable count (cfu/ml) for a
patient treated with rifampin.
EBA calculation. In the moxiﬂoxacin group, 8 out of 13 sub-
jects had complete data for Day 0 and Day 2 (ﬁve subjects were
excluded as they had missing data for Day 0 and/or Day 2). In
the isoniazid group, 12 out of 16 subjects were included in the
TABLE 2. MEAN TIME TO KILL 50% OF VIABLE BACILLI
FOR ISONIAZID, MOXIFLOXACIN, AND RIFAMPIN GROUPS
95% Confidence Interval for Mean
Drug n Mean vt50 (d) SD Lower Bound Upper Bound
Moxifloxacin 11 0.88 0.67 0.43 1.33
Isoniazid 14 0.46* 0.26 0.31 0.61
Rifampin 8 0.71 0.32 0.48 0.95
Total 33
Definition of abbreviation:v t 50  time to kill 50% of viable bacilli.
* Mean vt50 of isoniazid is significantly different from both moxifloxacin and
rifampin (asymptotic p  0.03) using the Kruskal–Wallis analysis of variance.
analysis of EBA in the isoniazid group. In all, 12 out of 14
subjects in the rifampin group had complete data for Day 0 and
Day2.ThemeanEBAvaluesarerecordedinTable3.Incontrast
tothevt50results,aKruskal–Wallisanalysisofvariancesuggested
that the isoniazid EBA was signiﬁcantly greater than that of
rifampin (asymptotic p  0.006), but there was no signiﬁcant
difference in the EBA of moxiﬂoxacin and both isoniazid and
rifampin.
Contamination of culture plates with environmental fungi
was responsible for all missing data points except in the case of
three subjects (two subjects treated with rifampin, both HIV
negative,andonesubjecttreatedwithmoxiﬂoxacin,HIV-positive)
where M. tuberculosis did not grow on the 7H11 media.
DISCUSSION
There are many major challenges facing clinicians working to
meet the global pandemic of tuberculosis. The ﬁrst is to identify
agents to treat drug-resistant tuberculosis. Others include devel-
oping regimens that shorten the length of therapy and treating
latent disease (1, 19).
Monotherapy studies provide the opportunity to assess the
bactericidal activity of new agents in human subjects (some of
the data presented in this paper was presented at a “Work in
Progress” meeting of the Royal Society of Tropical Medicine
and Hygiene, 2003 [21]). All previous studies have demonstrated
that isoniazid is the most bactericidal agent in current use. In
contrast, rifampin, which is also central to effective chemother-
apy, has only a modest activity in studies that have measured
the bactericidal activity over 2 days (18, 22). Our group believes
that this period is too short to measure activity and advocated a
minimum of 5-day studies (17). Our results conﬁrm prior studies
showing that isoniazid is highly bactericidal (our EBA  0.46
and SD  0.26, compared with prior EBAs of 0.43–0.72 and
SDs 0.17–0.54) (17, 18, 23–25). Our results for rifampin (EBA 
0.28, SD  0.71) are similar to results published elsewhere (0.19
[18], 0.29, SD  0.31 [23], and 0.20, SD  0.04 [24]).
This paper conﬁrms that moxiﬂoxacin’s activity, demon-
strated in vitro and in mouse models (7–11), extends to humans.
For moxiﬂoxacin, the time to reduce the viable count by 50%
(vt50) is 0.88 days (95% conﬁdence interval, 0.43–1.33), and when
calculated by the EBA methodology for bactericidal activity the
mean log fall in sputum viable count is 0.53 (95% conﬁdence
interval, 0.28–0.79). The activity of moxiﬂoxacin is similar to that
demonstrated for rifampin when calculated by both methods.
From our results, the EBA of moxiﬂoxacin (0.53) is higher
thanthatofciproﬂoxacin(0.20–0.21 [12,26])andoﬂoxacin(0.30)
(25). However, thevt50 for ciproﬂoxacin, 750 mg dailywas similar
to that of moxiﬂoxacin (0.79 and 0.88, respectively). We should
be cautious in comparing our data with other quinolones tested
TABLE 3. MEAN EARLY BACTERICIDAL ACTIVITY OF
ISONIAZID, MOXIFLOXACIN, AND RIFAMPIN GROUPS
95% CI for Mean
Drug n Mean EBA SD Lower Bound Upper Bound
Moxifloxacin 8 0.53 0.31 0.28 0.79
Isoniazid 12 0.77 0.37 0.54 1.00
Rifampin 12 0.28* 0.21 0.15 0.41
Total 32
Definition of abbreviations:C I confidence interval; EBA  early bactericidal
activity.
* Mean EBA of rifampin is significantly lower than that of isoniazid (asymptotic
p  0.01) using the Kruskal–Wallis analysis of variance.Gosling, Uiso, Sam, et al.: Bactericidal Activity of Moxifloxacin 1345
previously due to differences in methodology and small patient
groups.
It is notable that using the vt50 methodology we detected a
signiﬁcant difference between isoniazid and both rifampin and
moxiﬂoxacin. In contrast, using the EBA method we demon-
strated that rifampin alone has signiﬁcantly less activity than
isoniazid and that there is no difference between moxiﬂoxacin
and isoniazid. The reasons for these different results are not
clear. Evaluation of larger groups of patients may help detect a
signiﬁcant difference between the EBA of isoniazid and moxi-
ﬂoxacin.ThereissomedebateoverthemodelingofEBAstudies,
but there is general acceptance that exponential decay curves
correctly model the fall in viable bacilli in the early part of
treatment in the patient population used in these studies (27).
There are several limitations in this study. In the design of
the study, we planned to recruit at least ﬁve HIV-seropositive
subjectsin eachgroup However,our inclusioncriteriaof patients
having mild to moderate smear-positive pulmonary tuberculosis
led to the exclusion of most patients who were HIV-positive.
Consequently, it was impossible to draw any speciﬁc conclusions
to the activity of these agents in patients infected with HIV. In
the laboratory, we had high rates of fungal contamination, which
resulted in the loss of 25/215 (11.6%) data points and eight and
seven patients being excluded from the EBA and vt50 calcula-
tions, respectively.Drug susceptibility testing wasnot performed
and this may have been a limitation, but resistance to antituber-
culosis agents is low at our study site and previous studies de-
tected no quinolone-resistant M. tuberculosis (14).
The data reported in this paper conﬁrms that the excellent
in vitro activity of moxiﬂoxacin translates into activity in the
humanhost.Moxiﬂoxacinjoinsthesmallnumberofhighlybacte-
ricidal antituberculosis drugs and may contribute to the develop-
ment of more effective regimens. Further clinical studies are
neededtodeterminewhetherthe moxiﬂoxacinaddstothebacte-
ricidal activity of isoniazid or rifampin. Clinical trials to deter-
mine whether regimens containing moxiﬂoxacin bring higher
rates of culture conversion at 2 months should be performed as
soon as sufﬁcient safety data are available.
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